Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

作者：Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, Sergey Orlov, Mireille Cantarini, Remy B. Verheijen, Anders Mellemgaard, Lone H. Ottesen, Paul Frewer, Xiaoling Ou, Geoffrey R. Oxnard · 发表于：The Lancet Oncology · 年份：2020 · DOI：10.1016/s1470-2045(19)30785-5 · 被引用次数：418 · 研究领域：Lung Cancer Treatments and Mutations、Fibroblast Growth Factor Research、Lung Cancer Research Studies